DE60203260D1 - Pharmazeutische mischung gegen krebs, die ein 4-chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält - Google Patents
Pharmazeutische mischung gegen krebs, die ein 4-chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthältInfo
- Publication number
- DE60203260D1 DE60203260D1 DE60203260T DE60203260T DE60203260D1 DE 60203260 D1 DE60203260 D1 DE 60203260D1 DE 60203260 T DE60203260 T DE 60203260T DE 60203260 T DE60203260 T DE 60203260T DE 60203260 D1 DE60203260 D1 DE 60203260D1
- Authority
- DE
- Germany
- Prior art keywords
- chinazolinamine
- vinorelbine
- carboplatin
- paclitaxel
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C16/00—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes
- C23C16/22—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the deposition of inorganic material, other than metallic material
- C23C16/30—Deposition of compounds, mixtures or solid solutions, e.g. borides, carbides, nitrides
- C23C16/40—Oxides
- C23C16/401—Oxides containing silicon
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
- H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
- H01L21/02104—Forming layers
- H01L21/02107—Forming insulating materials on a substrate
- H01L21/02109—Forming insulating materials on a substrate characterised by the type of layer, e.g. type of material, porous/non-porous, pre-cursors, mixtures or laminates
- H01L21/02112—Forming insulating materials on a substrate characterised by the type of layer, e.g. type of material, porous/non-porous, pre-cursors, mixtures or laminates characterised by the material of the layer
- H01L21/02123—Forming insulating materials on a substrate characterised by the type of layer, e.g. type of material, porous/non-porous, pre-cursors, mixtures or laminates characterised by the material of the layer the material containing silicon
- H01L21/02126—Forming insulating materials on a substrate characterised by the type of layer, e.g. type of material, porous/non-porous, pre-cursors, mixtures or laminates characterised by the material of the layer the material containing silicon the material containing Si, O, and at least one of H, N, C, F, or other non-metal elements, e.g. SiOC, SiOC:H or SiONC
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
- H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
- H01L21/04—Manufacture or treatment of semiconductor devices or of parts thereof the devices having at least one potential-jump barrier or surface barrier, e.g. PN junction, depletion layer or carrier concentration layer
- H01L21/18—Manufacture or treatment of semiconductor devices or of parts thereof the devices having at least one potential-jump barrier or surface barrier, e.g. PN junction, depletion layer or carrier concentration layer the devices having semiconductor bodies comprising elements of Group IV of the Periodic System or AIIIBV compounds with or without impurities, e.g. doping materials
- H01L21/30—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26
- H01L21/31—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26 to form insulating layers thereon, e.g. for masking or by using photolithographic techniques; After treatment of these layers; Selection of materials for these layers
- H01L21/314—Inorganic layers
- H01L21/316—Inorganic layers composed of oxides or glassy oxides or oxide based glass
- H01L21/31604—Deposition from a gas or vapour
- H01L21/31633—Deposition of carbon doped silicon oxide, e.g. SiOC
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
- H01L2924/0001—Technical content checked by a classifier
- H01L2924/0002—Not covered by any one of groups H01L24/00, H01L24/00 and H01L2224/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26240201P | 2001-01-16 | 2001-01-16 | |
US262402P | 2001-01-16 | ||
PCT/US2002/001130 WO2002056912A2 (en) | 2001-01-16 | 2002-01-14 | Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60203260D1 true DE60203260D1 (de) | 2005-04-21 |
DE60203260T2 DE60203260T2 (de) | 2006-02-02 |
Family
ID=22997342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60203260T Expired - Lifetime DE60203260T2 (de) | 2001-01-16 | 2002-01-14 | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
Country Status (8)
Country | Link |
---|---|
US (6) | US7141576B2 (de) |
EP (1) | EP1353693B1 (de) |
JP (1) | JP4458746B2 (de) |
AT (1) | ATE290882T1 (de) |
AU (1) | AU2002236765A1 (de) |
DE (1) | DE60203260T2 (de) |
ES (1) | ES2236481T3 (de) |
WO (1) | WO2002056912A2 (de) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110300052A9 (en) * | 1997-05-21 | 2011-12-08 | Olsen Gary A | Particulate matter and methods of obtaining same from a kraft waste reclamation |
CA2238292A1 (en) * | 1997-05-21 | 1998-11-21 | S & S Lime, Inc. | Method of obtaining and using particulate calcium carbonate |
US20080219912A1 (en) * | 2007-03-06 | 2008-09-11 | Gary Allen Olsen | Particulate matter and methods of obtaining same from a kraft waste reclamation |
GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
DE60203260T2 (de) * | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
GB0119865D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
GB0119863D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
US7049313B2 (en) | 2002-02-25 | 2006-05-23 | Kudos Pharmaceuticals Ltd. | ATM inhibitors |
AU2003221684A1 (en) * | 2002-04-08 | 2003-10-27 | Smithkline Beecham Corporation | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor |
AU2003268087A1 (en) * | 2002-08-23 | 2004-03-11 | Ian Ma | Liposomal gemcitabine compositions for better drug delivery |
WO2005011607A2 (en) | 2003-08-01 | 2005-02-10 | Smithkline Beecham Corporation | Treatment of cancers expressing p95 erbb2 |
DE602004026071D1 (de) | 2003-08-13 | 2010-04-29 | Kudos Pharm Ltd | Aminopyrone und ihre verwendung als atm inhibitoren |
WO2005046678A1 (en) * | 2003-11-07 | 2005-05-26 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
EP1768963A4 (de) * | 2004-06-03 | 2009-06-10 | Smithkline Beecham Cork Ltd | Krebsbehandlungsverfahren |
CA2569139A1 (en) * | 2004-06-04 | 2005-12-22 | Smithkline Beecham (Cork) Limited | Lapatinib with letrozole for use in a treatment of breast cancer |
US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US20070238731A1 (en) | 2004-09-20 | 2007-10-11 | Kudos Pharmaceuticals Limited | Dna-Pk Inhibitors |
GB0427131D0 (en) * | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
KR20070107004A (ko) * | 2004-12-17 | 2007-11-06 | 스미스클라인 비이참 (코르크) 리미티드 | 암 치료 방법 |
US7642254B2 (en) | 2005-02-09 | 2010-01-05 | Kudos Pharmaceuticals Limited | ATM inhibitors |
MX2007009960A (es) | 2005-02-18 | 2008-03-11 | Abraxis Bioscience Inc | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
AR053358A1 (es) | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
MX2007013089A (es) | 2005-04-19 | 2008-01-14 | Smithkline Beecham Cork Ltd | Composicion farmaceutica. |
US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
US20080269131A1 (en) * | 2005-11-10 | 2008-10-30 | Smithkline Beecham Corporation | Inhibitors of Akt Activity |
WO2007058852A2 (en) * | 2005-11-10 | 2007-05-24 | Smithkline Beecham Corporation | Inhibitors of akt activity |
US20090005406A1 (en) | 2005-11-29 | 2009-01-01 | Smithkline Beecham Corporation | Cancer Treatment Method |
WO2007103758A2 (en) * | 2006-03-02 | 2007-09-13 | Smithkline Beecham Corporation | Thiazolones for use as pi3 kinase inhibitors |
MX2008013583A (es) * | 2006-04-26 | 2008-10-31 | Genentech Inc | Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen. |
CL2007001167A1 (es) | 2006-04-26 | 2008-01-25 | Genentech Inc | Compuestos derivados de pirimidina condensada, inhibidores de p13-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicionfarmaceutica. |
EP2023923A2 (de) * | 2006-05-25 | 2009-02-18 | Bristol-Myers Squibb Company | Verwendung von ixabepilon in kombination mit cyp3a4-hemmern für arzneimittel |
JP2010510990A (ja) * | 2006-11-28 | 2010-04-08 | スミスクライン ビーチャム (コーク) リミテッド | 癌の治療方法 |
EP2518074B1 (de) | 2006-12-07 | 2015-07-22 | F.Hoffmann-La Roche Ag | Phosphoinositid-3-Kinase-Hemmer-Verbindungen und Verfahren zur Verwendung |
US20100034816A1 (en) * | 2006-12-22 | 2010-02-11 | Novelix Therapeutics Gmbh | Treatment of Diabetes by at Least One Epidermal Growth Factor Receptor Specific Antibody or a Derivative Thereof |
US20100173914A1 (en) * | 2007-01-12 | 2010-07-08 | Hexi Chang | Pharmaceuticals, compositions and methods of making and using the same |
US20110160130A1 (en) * | 2007-02-16 | 2011-06-30 | Connie Erickson-Miller | Cancer treatment method |
UY30915A1 (es) * | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
US20110129550A1 (en) | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
US8288312B2 (en) * | 2007-03-06 | 2012-10-16 | S&S Lime, Inc. | Particulate matter and methods of obtaining same from a Kraft waste reclamation |
UY31137A1 (es) * | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
WO2009032651A1 (en) * | 2007-08-31 | 2009-03-12 | Smithkline Beecham Corporation | Inhibitors of akt activity |
CN101932587A (zh) | 2007-09-24 | 2010-12-29 | 吉宁特有限公司 | 噻唑并嘧啶pi3k抑制剂化合物及使用方法 |
KR101530402B1 (ko) * | 2007-10-09 | 2015-06-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 급성 인간 골수성 백혈병 세포를 죽이는 트롬보포이에틴 수용체 효능제 (tpora) |
JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain vehicles, installations and methods |
WO2009079541A1 (en) * | 2007-12-18 | 2009-06-25 | Smithkline Beecham (Cork) Limited | Quinazoline ditosylate anhydrate forms |
WO2009082687A1 (en) | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Azaindolizines and methods of use |
NZ602675A (en) | 2008-03-18 | 2014-03-28 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
US8252805B2 (en) | 2008-05-07 | 2012-08-28 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib ditosylate and processes for preparation thereof |
WO2009140144A1 (en) * | 2008-05-15 | 2009-11-19 | Teva Pharmaceutical Industries Ltd. | Forms of crystalline lapatinib and processes for preparation thereof |
WO2010017387A2 (en) * | 2008-08-06 | 2010-02-11 | Teva Pharmaceutical Industries Ltd. | Lapatinib intermediates |
EP2158912A1 (de) * | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Pharmazeutische Zusammensetzung mit N-[3-chlor-4-(3-fluorophenyl)methoxy)phenyl)6-(5(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furyl)-4-chinazolinamin |
US20100087459A1 (en) * | 2008-08-26 | 2010-04-08 | Leonid Metsger | Forms of lapatinib compounds and processes for the preparation thereof |
RU2683325C2 (ru) | 2009-02-05 | 2019-03-28 | Иммьюноджен, Инк. | Новые производные бензодиазепина |
JP5709766B2 (ja) | 2009-03-12 | 2015-04-30 | ジェネンテック, インコーポレイテッド | 造血器腫瘍の治療のためのホスホイノシチド3キナーゼ阻害剤化合物と化学療法剤の併用 |
US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
AR076262A1 (es) * | 2009-04-06 | 2011-06-01 | Eisai Inc | Derivados heterociclicos de diazepin-2-ona, composiciones farmaceuticas y sus usos en el tratamiento del cancer |
EP2416780B1 (de) * | 2009-04-06 | 2017-03-08 | Otsuka Pharmaceutical Co., Ltd. | Kombination von decitabin und cytidin-deaminase-inhibitor und ihre verwendung in der krebstherapie |
ES2628609T3 (es) * | 2009-04-06 | 2017-08-03 | Otsuka Pharmaceutical Co., Ltd. | Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer |
UA108863C2 (ru) | 2009-09-28 | 2015-06-25 | Ф. Хоффманн-Ля Рош Аг | Бензоксепиновые ингибиторы pi3 и их применение |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
MX352661B (es) | 2009-11-05 | 2017-12-04 | Rhizen Pharmaceuticals S A Star | Moduladores novedosos de benzopiran cinasa. |
US20110165155A1 (en) | 2009-12-04 | 2011-07-07 | Genentech, Inc. | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 |
CN102791715B (zh) | 2009-12-31 | 2016-04-27 | 卡洛斯三世国家癌症研究中心基金会 | 用作激酶抑制剂的三环化合物 |
CA2787714C (en) | 2010-01-22 | 2019-04-09 | Joaquin Pastor Fernandez | Inhibitors of pi3 kinase |
CN105001334A (zh) | 2010-02-10 | 2015-10-28 | 伊缪诺金公司 | Cd20抗体及其用途 |
CN102947302A (zh) | 2010-02-18 | 2013-02-27 | 西班牙国家癌症研究中心 | ***并[4,5-b]吡啶衍生物 |
PT2550269E (pt) * | 2010-03-23 | 2016-06-20 | Scinopharm Taiwan Ltd | Processo e intermediários para a preparação de lapatinib |
CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
NZ602385A (en) | 2010-03-29 | 2014-08-29 | Abraxis Bioscience Llc | Methods of treating cancer |
WO2011121317A1 (en) | 2010-04-01 | 2011-10-06 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors |
CN103140225A (zh) | 2010-06-04 | 2013-06-05 | 阿布拉科斯生物科学有限公司 | 治疗胰腺癌的方法 |
MY185130A (en) * | 2010-07-12 | 2021-04-30 | Celgene Corp | Romidepsin solid forms and uses thereof |
WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
ES2717657T3 (es) | 2011-02-15 | 2019-06-24 | Immunogen Inc | Métodos para la preparación de conjugados |
KR20140025434A (ko) | 2011-04-01 | 2014-03-04 | 제넨테크, 인크. | Akt 억제제 화합물 및 화학요법제의 조합물, 및 사용 방법 |
PL2705029T4 (pl) | 2011-05-04 | 2019-04-30 | Rhizen Pharmaceuticals S.A. | Nowe związki jako modulatory kinaz białkowych |
RU2598840C2 (ru) | 2011-05-19 | 2016-09-27 | Фундасион Сентро Насиональ Де Инвестигасионес Онколохикас Карлос Iii | Новые соединения |
EP2524918A1 (de) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazinderivate als Kinase Inhibitoren |
WO2013004984A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Tricyclic compounds for use as kinase inhibitors |
WO2013005057A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | New compounds |
WO2013005041A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Tricyclic heterocyclic compounds as kinase inhibitors |
WO2013182668A1 (en) | 2012-06-08 | 2013-12-12 | F. Hoffmann-La Roche Ag | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
CN103483324B (zh) * | 2012-06-12 | 2016-03-30 | 人福医药集团股份公司 | 拉帕替尼的新制备方法 |
PL2870157T3 (pl) | 2012-07-04 | 2018-01-31 | Rhizen Pharmaceuticals S A | Selektywne inhibitory pi3k delta |
EP2887965A1 (de) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Zytotoxische benzodiazepin-derivate |
EP2961435B1 (de) | 2013-02-28 | 2019-05-01 | ImmunoGen, Inc. | Konjugate mit zellbindenden mitteln und zytostatika |
WO2014134483A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
WO2014170910A1 (en) | 2013-04-04 | 2014-10-23 | Natco Pharma Limited | Process for the preparation of lapatinib |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
AR104068A1 (es) | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
AU2017321973A1 (en) | 2016-09-02 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
WO2018227112A1 (en) * | 2017-06-09 | 2018-12-13 | The Trustees Of Columbia University In The City Of New York | Short tat oligomers for drug delivery |
CN108285421A (zh) * | 2018-01-26 | 2018-07-17 | 黑龙江鑫创生物科技开发有限公司 | 一种微通道反应器合成拉帕替尼中间体的方法 |
WO2019161263A1 (en) * | 2018-02-16 | 2019-08-22 | Ohio State Innovation Foundation | Lipid-surfactant nanoparticles for drug delivery and methods of making and uses thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9423997D0 (en) | 1994-11-28 | 1995-01-11 | Erba Carlo Spa | Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation |
FR2729295A1 (fr) * | 1995-01-17 | 1996-07-19 | Rhone Poulenc Rorer Sa | Traitement therapeutique combine des pathologies hyperproliferatives |
CA2227205C (en) | 1995-07-21 | 2007-05-01 | Constantia Gruppe | Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
EP0932399B1 (de) * | 1996-03-12 | 2006-01-04 | PG-TXL Company, L.P. | Wasserlösliche paclitaxel-prodrogen |
PT912559E (pt) | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase |
ID19430A (id) | 1996-07-13 | 1998-07-09 | Glaxo Group Ltd | Senyawa senyawa heterosiklik |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
JP2000072749A (ja) | 1998-08-24 | 2000-03-07 | Mitsui Chemicals Inc | キノリン誘導体を用いるアポトーシス誘導剤 |
US6630124B1 (en) | 1998-10-16 | 2003-10-07 | Ramot-University Authority For Applied Research And Industrial Development Ltd. | Combination therapy with VIP antagonist |
US6333348B1 (en) * | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
US6316462B1 (en) * | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
US6713632B1 (en) | 1999-06-22 | 2004-03-30 | Takeda Chemical Industries, Ltd. | Process for the preparation of imidazole derivatives |
ES2295035T3 (es) * | 1999-07-09 | 2008-04-16 | Glaxo Group Limited | Anilinoquinazolinas como inhibidores de proteina tirosina quinasa. |
DE19947028A1 (de) * | 1999-09-30 | 2001-04-12 | Siemens Ag | Thyristor mit Spannungsstoßbelastbarkeit in der Freiwerdezeit |
CZ299561B6 (cs) | 2000-06-30 | 2008-09-03 | Glaxo Group Limited | Chinazolinaminový derivát a farmaceutický prostredek |
DE60203260T2 (de) * | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
-
2002
- 2002-01-14 DE DE60203260T patent/DE60203260T2/de not_active Expired - Lifetime
- 2002-01-14 JP JP2002557419A patent/JP4458746B2/ja not_active Expired - Lifetime
- 2002-01-14 EP EP02703127A patent/EP1353693B1/de not_active Expired - Lifetime
- 2002-01-14 AU AU2002236765A patent/AU2002236765A1/en not_active Abandoned
- 2002-01-14 AT AT02703127T patent/ATE290882T1/de not_active IP Right Cessation
- 2002-01-14 ES ES02703127T patent/ES2236481T3/es not_active Expired - Lifetime
- 2002-01-14 WO PCT/US2002/001130 patent/WO2002056912A2/en active IP Right Grant
- 2002-01-14 US US10/466,290 patent/US7141576B2/en not_active Expired - Lifetime
-
2006
- 2006-10-11 US US11/548,413 patent/US20070148261A1/en not_active Abandoned
-
2010
- 2010-06-15 US US12/815,831 patent/US20100249160A1/en not_active Abandoned
-
2011
- 2011-09-01 US US13/223,480 patent/US20110312982A1/en not_active Abandoned
- 2011-11-11 US US13/294,496 patent/US8444988B2/en not_active Expired - Lifetime
-
2015
- 2015-08-21 US US14/831,909 patent/US20150366868A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002056912A2 (en) | 2002-07-25 |
US8444988B2 (en) | 2013-05-21 |
EP1353693A2 (de) | 2003-10-22 |
DE60203260T2 (de) | 2006-02-02 |
ES2236481T3 (es) | 2005-07-16 |
WO2002056912A3 (en) | 2003-05-22 |
US20150366868A1 (en) | 2015-12-24 |
JP4458746B2 (ja) | 2010-04-28 |
ATE290882T1 (de) | 2005-04-15 |
EP1353693B1 (de) | 2005-03-16 |
US20070148261A1 (en) | 2007-06-28 |
US7141576B2 (en) | 2006-11-28 |
AU2002236765A1 (en) | 2002-07-30 |
US20120058113A1 (en) | 2012-03-08 |
US20110312982A1 (en) | 2011-12-22 |
US20040053946A1 (en) | 2004-03-18 |
JP2004523522A (ja) | 2004-08-05 |
US20100249160A1 (en) | 2010-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60203260D1 (de) | Pharmazeutische mischung gegen krebs, die ein 4-chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält | |
BRPI0412798A (pt) | uso de uma combinação de um antagonista de fator de crescimento endotelial vascular e um agente antiproliferativo, método de inibir ou reduzir o crescimento de tumor, composição farmacêutica, uso de uma combinação de um antagonista de vegf e um agente quimioterapêutico, e, artigo de fabricação | |
EA200401318A1 (ru) | Производные хинолинона | |
HK1053115A1 (en) | Quinazoline derivatives for the treatment of tumours. | |
IL164135A (en) | 4-anilino quinazoline derivatives as antiproliferative agents, process for their preparation, pharmaceutical compositions containing such derivatives and use thereof for the preparation of medicaments for the treatment of cancer | |
NZ621449A (en) | Treatment with anti-vegf antibodies | |
MY129809A (en) | Quinazoline derivatives | |
IL174154A (en) | History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines | |
CY1114359T1 (el) | Παραγοντας κατα ογκων περιλαμβανων τον αναστολεα αποακετυλασης ιστονης fk228 kai ton αναστολεα τοποϊσομερασης ιι δοξορουβικινη | |
AR053338A1 (es) | Terapia antiproliferativa combinada usando ciertos agentes quimioterapeuticos basados en platino y taxanos | |
AR027355A1 (es) | Acidos tiazolidincarboxilicos | |
TW200635923A (en) | Tricyclic heterocycles, their manufacture and use as pharmaceutical agents | |
ATE293995T1 (de) | Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten | |
ATE450265T1 (de) | Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält | |
NZ516349A (en) | Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease | |
WO2005105094A3 (en) | Cancer treatment method | |
AR037346A1 (es) | Terapia de combinacion | |
BRPI0407234A (pt) | Heterociclos substituìdos | |
ATE495793T1 (de) | Antitumorzusammensetzungen welche ecteinascidin 743 enthalten | |
DE60229046D1 (de) | Chinazolin derivate | |
ATE319718T1 (de) | Oxazolo- und furopyrimidine und deren verwendung als medikamente gegen tumore | |
ATE376824T1 (de) | Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln | |
ATE466008T1 (de) | P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält | |
NO20024076D0 (no) | Sammensetning omfattende camptotecin og et pyrimidinderivat for behandling av cancer | |
EE200300429A (et) | Tegafuri, uratsiili, foliinhappe, paklitakseeli ja karboplatiini kasutamine ravimkoostise valmistamiseks kasvaja raviks |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |